This review provides an overview of evidence supporting use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the most recently approved AOM class and among the most efficacious ones.18,19 We discuss the role of OBGYNs in obesity care and suggest strategies for the initiation and maintenance of GLP-1 RA therapy, such as management of common side effects, to ensure that their patients achieve optimal therapeutic response. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.